skip to Main Content

Expected impact for the practitioners

Expected Impact: Emerging data-driven analytics and advanced simulation methods to study causal mechanisms and improve forecasts of ill-health, identification of disease trajectories and
Expected Impact: Better and faster means of high-quality response to prevent or timely address development of new medical conditions and/or improve the quality of life.
Expected Impact: Better knowledge for improved patient counselling as well as to improve follow-up of patients; PERSIST big data model will contribute to create entirely new knowledge and understanding on how patient behaviours and various patient-specific co-morbidities may influence health outcomes. This knowledge will support the expected impact by:

I. Providing an improved forecast of ill health by predicting individual patient trajectories.

PERSIST will contribute with specific impact on data-driven analytics over personal health data, providing a unique approach for predicting individual patient trajectories based on user profile modelling (including newly sensed prospective data). The cohorts learned from data and the developed trajectories will be evaluated as to their ability for reconstructing patients’ events and measuring health status changes as well as quantifying risks.

Indicator: (1) Patient profile model accuracy according to its capacity to effectively anticipate trajectory events, and risks; (2) Data analytics scalability through the increased and sustainable data processing and analytics over large and heterogeneous datasets comprising EHR; sensor data sources and other supporting information; (3) Provision of reliable forecasted information for the creation of dynamic follow-up strategies for oncologist to provide equality and fair attention to any patient based on factual data.

II. Providing a clinical decision support system to facilitate timely medical interventions and improve patient counselling.

PERSIST will enable to process and represent evidence to support the clinical decisions regarding diagnosis, treatment and follow-up data of cancer patients based on each individual patient data model, predicted trajectories and the risk stratification. This will allow detecting anomalies in their personal predicted trajectory – new risks not detected with current practices – and practitioners will have a better insight on which focus areas of improvement they/the patient should focus at individual level. This allows faster response to timely address patient safety. These outcomes will mainly influence the provision of personalised survivorship care plans and follow up strategies based on each individual patient profile to improve patient counselling.

Indicator: (1) Time-to-completion for specified tasks related to intervention before and after CDSS roll-out; (2) Rate at which practitioners override alerts; (3) Adherence to clinical guidelines for selected care pathways; (4) Time-to-order for critical medications/procedures; (5) Time-to-order for critical procedures; (6) #diagnosis of recurrence cancer; (7) #secondary diseases detected; (8) Sensitivity and specificity of the CDSS; (9) Usability perception of the associated risk factors and the wellbeing/lifestyle factors.

As a major impact, PERSIST has the potential to dramatically improve the selection of the best treatments, avoiding the harming of patients and the use of ineffective therapies. PERSIST contributes to the provision of evidence-based methods to increase health care delivery efficiency and to increase follow-up efficacy. Additionally, it will pave the way for new scientific research by presenting new evidence-based treatment methods and approaches.


Closing conference for project PERSIST in Madrid: We persist! The future is in our hands.

Under this slogan the PERSIST consortium held the closing conference for project PERSIST in Madrid on February 15th, 2023. The event took place in the headquarters of the European Commission Representation in Spain and was opened by Mr. Ioannis Virvilis,…

CHU de Liege presents PERSIST to patients

On December 2 and 3, the Liège University hospital officially opened the doors of its Comprehensive Cancer Center (ICAB). The activities of Radiotherapy, Nuclear Medicine and Oncological Imaging, as well as the medical practices, the management of clinical studies, and…

WEBINAR “PERSIST: A digital solution for continuum of care after cancer”

WHEN: 1 December, 2022 / 15:00-16:00 CET WHERE: MS Teams; LINK TO JOIN: LINK TO REGISTRATION FORM: : Project PERSIST is announcing a public final technical webinar online on the 1st of December at 15.00 CET. The PERSIST H2020…

“PERSISTent to fight cancer, whatever I.T. takes” – А successful and productive event for PERSIST took place in the EU Parliament

In the Cancer Awareness Month the PERSIST consortium organized a hybrid event in the European Parliament on October 13, 2022. Among other objectives, the event aimed to raise awareness and improve the understanding among stakeholders on the key benefits from…

PERSIST Event: PERSISTent to fight cancer, whatever I.T. takes

13 October 2022, 9:00 – 10:40 CET, European Parliament, Brussels Digital health and care refer to tools and services that use information and communication technologies to improve prevention, diagnosis, treatment, monitoring and management of health-related issues and to monitor and…

Meeting of PERSIST consortium partners in Sierre, Switzerland

After two years of working in an online setting, due to the COVID-19 situation in Europe, the partners from the PERSIST consortium had the chance to meet in person in the beautiful town of Sierre, Switzerland. The meeting aimed to…

Back To Top